摘要
目的探讨胃肠道间质瘤(GISTs)的临床病理、免疫组化特征及预后相关因素。方法103例胃肠道间质瘤患者接受手术后分析其病理形态学,观察肿瘤大小、细胞核异性型和核分裂相,并根据这些指标进行分型。检测肿瘤组织CD117和CD34免疫学表型。结果本组103例胃肠道间质瘤中CD117阳性表达93例(90.3%),CD34阳性表达69例(70.0%),不同部位GISTs其CD117和CD34表达无显著差异(P>0.05)。良性肿瘤患者的三年无病生存率显著地高于恶性肿瘤(P<0.05)。结论CD34和CD117联合使用可协助鉴别诊断GISTs。基于肿瘤大小、细胞异型性以及核分裂相等的组织形态学分型可作为诊断恶性GISTs参考指标。
Objective To investigate clinicopathologic and immunohistochemical features and prognosis-related factors in gastrointestinal stromal tumors. Methods One hundred and three patients with gastrointestinal stromal tumors were studied. Pathomorphology in these patients were analysed after surgical op- erations. GSITs were divided into Benign and malignant tumor according to tumor size,mitosis and atypism. Irnmunohistochemistry was performed by the streptavidin peroxidase conjugaed method using a monoclonal antibody specifically against CD117 and CD34. Results Irnmunohistochemical expressions of CD34 and CD117 protein were detected in 90. 3% （93/103） and 70. 0% （69/103） patients, respectively. There were not significant differences among different sites of digestive tract（P〉0. 05）. 3-year free-diseased survival in patients with benign tumors was significantly higher than those with malignant tumors （P〈0.05）. Conclusion CD117 and CD34 tumor marker may help to diagnose gastrointestinal stromal tumors. Pathomorphological features on the basis of tumor size, mitosis and atypism can provide useful information for the prognosis of GST patients.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2007年第11期864-867,共4页
Cancer Research on Prevention and Treatment
关键词
胃间质瘤
临床病理
免疫组化
预后
gastrointestinal stromal tumors（GISTs）
Clinicopathology
Immunohistochemistry
prognosis
